Cargando…

3,6-Disubstituted 1,2,4-Triazolo[3,4-b]Thiadiazoles with Anticancer Activity Targeting Topoisomerase II Alpha

BACKGROUND: Topoisomerase IIα (topIIα) maintains the topology of DNA in order to ensure the proper functioning of numerous DNA processes. Inhibition of topIIα leads to the killing of cancer cells thus constituting such inhibitors as useful tools in cancer therapeutics. Triazolo[3,4-b]thiadiazole der...

Descripción completa

Detalles Bibliográficos
Autores principales: Sagredou, Sofia, Dalezis, Panagiotis, Nikoleousakos, Nikolaos, Nikolaou, Michail, Voura, Maria, Almpanakis, Konstantinos, Panayiotidis, Mihalis I, Sarli, Vasiliki, Trafalis, Dimitrios T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395825/
https://www.ncbi.nlm.nih.gov/pubmed/32801761
http://dx.doi.org/10.2147/OTT.S254856
_version_ 1783565475520708608
author Sagredou, Sofia
Dalezis, Panagiotis
Nikoleousakos, Nikolaos
Nikolaou, Michail
Voura, Maria
Almpanakis, Konstantinos
Panayiotidis, Mihalis I
Sarli, Vasiliki
Trafalis, Dimitrios T
author_facet Sagredou, Sofia
Dalezis, Panagiotis
Nikoleousakos, Nikolaos
Nikolaou, Michail
Voura, Maria
Almpanakis, Konstantinos
Panayiotidis, Mihalis I
Sarli, Vasiliki
Trafalis, Dimitrios T
author_sort Sagredou, Sofia
collection PubMed
description BACKGROUND: Topoisomerase IIα (topIIα) maintains the topology of DNA in order to ensure the proper functioning of numerous DNA processes. Inhibition of topIIα leads to the killing of cancer cells thus constituting such inhibitors as useful tools in cancer therapeutics. Triazolo[3,4-b]thiadiazole derivatives are known for their wide range of pharmacological activities while previous studies have documented their in vitro anticancer activity. The purpose of the current study was to investigate if these chemical compounds can act as topIIα inhibitors in cell-free and cell-based systems. MATERIALS AND METHODS: The MTT assay was performed in DLD-1, HT-29, and LoVo cancer cells so as to evaluate the antiproliferative activity of KA25, KA26, and KA39 triazolo[3,4-b]thiadiazole derivatives. The KA39 compound was tested as a potential topIIα inhibitor using the plasmid-based topoisomerase II drug screening kit. The inhibitory effect of the three derivatives on topIIα phosphorylation was studied in HT-29 and LoVo cancer cells according to Human Phospho-TOP2A/Topoisomerase II Alpha Cell-Based Phosphorylation ELISA Kit. Moreover, flow cytometry was utilized in order to explore apoptotic induction and cell cycle growth arrest, upon treatment with KA39, in DLD-1 and HT-29 cells, respectively. In silico studies were also carried out for further investigation. RESULTS: All three triazolo[3,4-b]thiadiazole derivatives showed an in vitro antiproliferative effect with the KA39 compound being the most potent one. Our results indicated that KA39 induced both early and late apoptosis as well as cell cycle growth arrest in S phase. In addition, the compound blocked the relaxation of supercoiled DNA while it also inhibited topIIα phosphorylation (upon treatment; P<0.001). CONCLUSION: Among the three triazolo[3,4-b]thiadiazole derivatives, KA39 was shown to be the most potent anticancer agent and catalytic inhibitor of topIIα phosphorylation as well.
format Online
Article
Text
id pubmed-7395825
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73958252020-08-13 3,6-Disubstituted 1,2,4-Triazolo[3,4-b]Thiadiazoles with Anticancer Activity Targeting Topoisomerase II Alpha Sagredou, Sofia Dalezis, Panagiotis Nikoleousakos, Nikolaos Nikolaou, Michail Voura, Maria Almpanakis, Konstantinos Panayiotidis, Mihalis I Sarli, Vasiliki Trafalis, Dimitrios T Onco Targets Ther Original Research BACKGROUND: Topoisomerase IIα (topIIα) maintains the topology of DNA in order to ensure the proper functioning of numerous DNA processes. Inhibition of topIIα leads to the killing of cancer cells thus constituting such inhibitors as useful tools in cancer therapeutics. Triazolo[3,4-b]thiadiazole derivatives are known for their wide range of pharmacological activities while previous studies have documented their in vitro anticancer activity. The purpose of the current study was to investigate if these chemical compounds can act as topIIα inhibitors in cell-free and cell-based systems. MATERIALS AND METHODS: The MTT assay was performed in DLD-1, HT-29, and LoVo cancer cells so as to evaluate the antiproliferative activity of KA25, KA26, and KA39 triazolo[3,4-b]thiadiazole derivatives. The KA39 compound was tested as a potential topIIα inhibitor using the plasmid-based topoisomerase II drug screening kit. The inhibitory effect of the three derivatives on topIIα phosphorylation was studied in HT-29 and LoVo cancer cells according to Human Phospho-TOP2A/Topoisomerase II Alpha Cell-Based Phosphorylation ELISA Kit. Moreover, flow cytometry was utilized in order to explore apoptotic induction and cell cycle growth arrest, upon treatment with KA39, in DLD-1 and HT-29 cells, respectively. In silico studies were also carried out for further investigation. RESULTS: All three triazolo[3,4-b]thiadiazole derivatives showed an in vitro antiproliferative effect with the KA39 compound being the most potent one. Our results indicated that KA39 induced both early and late apoptosis as well as cell cycle growth arrest in S phase. In addition, the compound blocked the relaxation of supercoiled DNA while it also inhibited topIIα phosphorylation (upon treatment; P<0.001). CONCLUSION: Among the three triazolo[3,4-b]thiadiazole derivatives, KA39 was shown to be the most potent anticancer agent and catalytic inhibitor of topIIα phosphorylation as well. Dove 2020-07-28 /pmc/articles/PMC7395825/ /pubmed/32801761 http://dx.doi.org/10.2147/OTT.S254856 Text en © 2020 Sagredou et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sagredou, Sofia
Dalezis, Panagiotis
Nikoleousakos, Nikolaos
Nikolaou, Michail
Voura, Maria
Almpanakis, Konstantinos
Panayiotidis, Mihalis I
Sarli, Vasiliki
Trafalis, Dimitrios T
3,6-Disubstituted 1,2,4-Triazolo[3,4-b]Thiadiazoles with Anticancer Activity Targeting Topoisomerase II Alpha
title 3,6-Disubstituted 1,2,4-Triazolo[3,4-b]Thiadiazoles with Anticancer Activity Targeting Topoisomerase II Alpha
title_full 3,6-Disubstituted 1,2,4-Triazolo[3,4-b]Thiadiazoles with Anticancer Activity Targeting Topoisomerase II Alpha
title_fullStr 3,6-Disubstituted 1,2,4-Triazolo[3,4-b]Thiadiazoles with Anticancer Activity Targeting Topoisomerase II Alpha
title_full_unstemmed 3,6-Disubstituted 1,2,4-Triazolo[3,4-b]Thiadiazoles with Anticancer Activity Targeting Topoisomerase II Alpha
title_short 3,6-Disubstituted 1,2,4-Triazolo[3,4-b]Thiadiazoles with Anticancer Activity Targeting Topoisomerase II Alpha
title_sort 3,6-disubstituted 1,2,4-triazolo[3,4-b]thiadiazoles with anticancer activity targeting topoisomerase ii alpha
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395825/
https://www.ncbi.nlm.nih.gov/pubmed/32801761
http://dx.doi.org/10.2147/OTT.S254856
work_keys_str_mv AT sagredousofia 36disubstituted124triazolo34bthiadiazoleswithanticanceractivitytargetingtopoisomeraseiialpha
AT dalezispanagiotis 36disubstituted124triazolo34bthiadiazoleswithanticanceractivitytargetingtopoisomeraseiialpha
AT nikoleousakosnikolaos 36disubstituted124triazolo34bthiadiazoleswithanticanceractivitytargetingtopoisomeraseiialpha
AT nikolaoumichail 36disubstituted124triazolo34bthiadiazoleswithanticanceractivitytargetingtopoisomeraseiialpha
AT vouramaria 36disubstituted124triazolo34bthiadiazoleswithanticanceractivitytargetingtopoisomeraseiialpha
AT almpanakiskonstantinos 36disubstituted124triazolo34bthiadiazoleswithanticanceractivitytargetingtopoisomeraseiialpha
AT panayiotidismihalisi 36disubstituted124triazolo34bthiadiazoleswithanticanceractivitytargetingtopoisomeraseiialpha
AT sarlivasiliki 36disubstituted124triazolo34bthiadiazoleswithanticanceractivitytargetingtopoisomeraseiialpha
AT trafalisdimitriost 36disubstituted124triazolo34bthiadiazoleswithanticanceractivitytargetingtopoisomeraseiialpha